“Closed Loop Medicine, the Babraham Research Campus therapeutics and health technology business, has secured a £250,000 COVID-19 Innovate UK Continuity Funding award to support its ongoing clinical research programme.
This was previously secured through the Innovate UK Precision Medicine Accelerator awarded to Closed Loop Medicine last year to develop a precision drug + digital therapy package for patients with high blood pressure; the next stage of the project was to enter into clinical studies in April this year before coronavirus intervened.
The study is being run in partnership with the William Harvey Clinical Research Centre, Queen Mary University of London, part of the National Institute for Health Research (NIHR) Biomedical Research Centre at Barts (BRC).
The COVID-19 pandemic saw a nationwide pause and review of clinical trials so CLM’s study was placed on hold as the pandemic broke out. During the early stages of the pandemic, research highlighted the potential for a link between COVID-19 mortality and high blood pressure.”